Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Stem cell therapy for vocal fold regeneration after scarring: a review of experimental approaches

Svistushkin MV., Kotova S., Shpichka A., Starostina S., Shekhter A., Bikmulina P.

Clinical Trial on Scar, published in Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cell Res Ther (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35505357
PMCID
PMC9066721
DOI
10.1186/s13287-022-02853-9
Citations
8

Abstract (original English)

This review aims at becoming a guide which will help to plan the experimental design and to choose adequate methods to assess the outcomes when testing cell-based products in the treatment of the damaged vocal folds. The requirements to preclinical trials of cell-based products remain rather hazy and dictated by the country regulations. Most parameters like the way the cells are administered, selection of the cell source, selection of a carrier, and design of in vivo studies are decided upon by each research team and may differ essentially between studies. The review covers the methodological aspects of preclinical studies such as experimental models, characterization of cell products, assessment of the study outcome using molecular, morphological and immunohistochemical analyses, as well as measuring the tissue physical properties. The unified recommendations to perform preclinical trials could significantly facilitate the translation of cell-based products into the clinical practice.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Vocal CordsCicatrixHumansStem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research